Hi all,
please educate me if I'm wrong, however my understanding as far as the HSV-2 trail goes that because of the delay in vetting suitable candidates it is in effect two groups of 20 NOT a group of 40 and therefore 2 groups of 6 months, as such if the protocols are not changed for the second group it would be improbable that a superior result be obtained in the second group. So if 58% was achieved again it would in fact validate the first half of the trail in a positive manner. Talking to JC earlier in FEB he indicated that dosage frequency/amounts would be changed as part of the trails going forward but didn't indicate if would be adjusted for the second 20 participants of HSV-2. Lastly he also talked about duration and as has been stated here that the longer you on it the better the effect so after say 9 months a greater result would be achieved. So if the first 20 continued to be boosted sure a higher value would be achieved however my understanding is that both groups will be treated the same and in effect that means 2 6month trails conducted in the same manner with hopefully the same number 58%.
- Forums
- ASX - By Stock
- AVR
- "Take a Closer Look"
"Take a Closer Look", page-514
-
- There are more pages in this discussion • 714 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M |
Open | High | Low | Value | Volume |
$10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $9.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.91 | 475 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 9.800 |
1 | 200 | 9.600 |
1 | 2 | 9.540 |
1 | 330 | 9.510 |
2 | 1185 | 9.500 |
Price($) | Vol. | No. |
---|---|---|
9.910 | 475 | 2 |
9.990 | 99 | 1 |
10.000 | 250 | 1 |
10.500 | 10005 | 2 |
11.000 | 5000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online